Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
An evidence-based review of AOD-9604 (HGH fragment 176-191) safety signals in the FDA Adverse Event Reporting System, regulatory status, and what clinicians should know about post-market surveillance for this compounded peptide.
Read clinical reviewAOD-9604 has never received FDA approval. Review the full regulatory timeline, failed clinical trials, FDA compounding restrictions, and what this means for patients considering this peptide.
Read clinical reviewA complete regulatory timeline of AOD-9604 (HGH fragment 176-191) from 2020 through 2026, covering FDA bulk drug substance evaluations, compounding pharmacy oversight, warning letters, and safety data.
Read clinical reviewAOD-9604 (HGH fragment 176-191) has never received FDA approval. This article examines its patent history, FDA warning letters, regulatory classification disputes, and the legal field for compounding pharmacies.
Read clinical reviewAOD-9604 remains unapproved by the FDA with no active IND or NDA on file. This article covers its regulatory history, compounding status, safety data, and whether next-generation peptide fat-loss agents will surpass it.
Read clinical reviewHow the FDA and EMA treat AOD-9604 (HGH fragment 176-191) differently. Covers approval status, compounding access under 503A, European classification, clinical trial history, and safety data gaps.
Read clinical review